TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6204413

Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 ng/kg/min before CPB and 50 ng/kg/min during CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (3 mg/kg heparin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion before CPB
Number of subjects: 20
Study: 31228612

Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected finger joint (P50)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Painful stimulation at non-affected thumbnail (P50)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected joint
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Painful stimulation at disease-affected joints
Number of subjects: 31
Study: 30325656

Group type: EXPERIMENTAL
Intervention: MiniMed 640G system with continuous glucose monitoring (CGM) and SmartGuard PLGM feature for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: MiniMed 640G without CGM and with blinded continuous glucose measurements
Number of subjects: 0
Study: 26581889

Group type: EXPERIMENTAL
Intervention: Challenge with ETEC strain H10407
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rechallenge with ETEC strain H10407
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial challenge with ETEC strain H10407
Number of subjects: 0
Study: 24825343

Group type: EXPERIMENTAL
Intervention: Pre-dialysis heparin coating of the membrane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intermittent saline flushes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Constant saline infusion
Number of subjects: 46
Study: 21954198

Group type: EXPERIMENTAL
Intervention: Patient decision aid (videobooklet)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Patient decision aid (videobooklet) + adaptive conjoint analysis (ACA) tool
Number of subjects: 208

Group type: COMPARATOR
Intervention: Educational booklet on OA management (control)
Number of subjects: 208
Study: 21105281

Group type: EXPERIMENTAL
Intervention: Risperidone at 6 mg/d plus buspirone at 60 mg/d
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone at 6 mg/d plus placebo
Number of subjects: 46
Study: 18180629

Group type: EXPERIMENTAL
Intervention: 200 U of BTXA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15818699

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 12842375

Group type: EXPERIMENTAL
Intervention: Oral opioid analgesia
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-opioid analgesia
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 10658520

Group type: EXPERIMENTAL
Intervention: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) with ifosfamide
Number of subjects: 505

Group type: COMPARATOR
Intervention: Carboplatin (200 mg/m2) and cisplatin (60 mg/m2) without ifosfamide
Number of subjects: 505
Study: 8889289

Group type: EXPERIMENTAL
Intervention: Enadoline 25 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enadoline 15 micrograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg i.m.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enadoline (2, 5, 15 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACET/COD combination
Number of subjects: 0
Study: 2060561

Group type: EXPERIMENTAL
Intervention: Salbutamol (500-4000 micrograms)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isoprenaline (500-4000 micrograms)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isoprenaline and Salbutamol (500-4000 micrograms)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6209500

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg tid)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin (after placebo)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metformin (during treatment)
Number of subjects: 15
Study: 31603076

Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagal Nerve Stimulation (t-VNS) using GammaCore device for 2 weeks, self-administered three times per day.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment for 2 weeks, self-administered three times per day.
Number of subjects: 21
Study: 30201050

Group type: EXPERIMENTAL
Intervention: Three‐dimensionally integrated exercise for scoliosis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care of observation following the Scoliosis Research Society criteria
Number of subjects: 42
Study: 28852716

Group type: EXPERIMENTAL
Intervention: Dry cupping therapy on the abdominal wall for 8 minutes every other day for 4 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard laxative therapy (Polyethylene glycol (PEG) 40% solution without electrolyte), 0.4 g/kg once daily for 4 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dry cupping therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard laxative therapy
Number of subjects: 120
Study: 24614829

Group type: EXPERIMENTAL
Intervention: Upper extremity progressive resistance exercises (PRE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Endurance exercises (EE)
Number of subjects: 19
Study: 23088650

Group type: EXPERIMENTAL
Intervention: Bortezomib-rituximab
Number of subjects: 676

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 676
Study: 20202349

Group type: EXPERIMENTAL
Intervention: Standardized guidelines for reporting RCTs (REFLECT statement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications to the CONSORT statement for livestock trials
Number of subjects: 0
Study: 17623805

Group type: EXPERIMENTAL
Intervention: meat-sweet dietary pattern (4th quartile)
Number of subjects: 2995

Group type: EXPERIMENTAL
Intervention: meat-sweet dietary pattern (4th quartile) in postmenopausal women with estrogen receptor-positive tumors
Number of subjects: 2995

Group type: EXPERIMENTAL
Intervention: vegetable-soy dietary pattern
Number of subjects: 2995
Study: 17666216

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) specific IL-5 responses at 3 years
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: House dust mite (HDM) specific IL-5 responses at 5 years
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Other HDM-specific cytokine responses
Number of subjects: 370

Group type: COMPARATOR
Intervention: HDM avoidance intervention
Number of subjects: 370
Study: 15066880

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Low level of vigorous physical activity
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Meeting behavioral guidelines for physical activity
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Sedentary behavior and dietary fiber guidelines
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Minority background (Hispanic or other)
Number of subjects: 878
Study: 11413350

Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation (NMV) for 1 year in volume cycled mode
Number of subjects: 33
Study: 9250103

Group type: EXPERIMENTAL
Intervention: Tea flavonoids (black tea)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tea flavonoids (in vitro)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Theaflavins (in vitro)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no tea consumption)
Number of subjects: 14
Study: 8513736

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (1.5 mmols and above)
Number of subjects: 53
Study: 3593627

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.2% (w/w) triclosan
Number of subjects: 12
Study: 29458229

Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Delayed Closure (DC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both PC and DC
Number of subjects: 38
Study: 28810136

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 123
Study: 25916923

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by lactate clearance rate (LC) and central venous oxygen saturation (ScvO₂)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluid resuscitation guided by central venous oxygen saturation (ScvO₂) alone
Number of subjects: 100
Study: 23608794

Group type: EXPERIMENTAL
Intervention: Golden Bifid 2.0 g, bid for 24 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Changmei 1.0 g, tid for 24 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of Golden Bifid and Changmei for 24 months
Number of subjects: 60
Study: 21340624

Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5
Number of subjects: 163185

Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5 combined with HbA(1c) ≥ 6.0%
Number of subjects: 163185

Group type: EXPERIMENTAL
Intervention: SCORE ≥ 5 combined with glucose measures
Number of subjects: 163185

Group type: EXPERIMENTAL
Intervention: Glucose measures alone
Number of subjects: 163185

Group type: EXPERIMENTAL
Intervention: HbA(1c) alone
Number of subjects: 163185
Study: 19218299

Group type: EXPERIMENTAL
Intervention: Accelerometry
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-report measures of physical activity
Number of subjects: 74
Study: 17204901

Group type: EXPERIMENTAL
Intervention: Elastic-band method
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Temporal placement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mastoid placement
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Forehead placement
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unoccluded condition
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Occluded condition
Number of subjects: 38
Study: 15204011

Group type: EXPERIMENTAL
Intervention: 2 mg xaliproden
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12408777

Group type: EXPERIMENTAL
Intervention: GEM (Arm A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: GEM + CDDP (Arm B)
Number of subjects: 42
Study: 9824789

Group type: EXPERIMENTAL
Intervention: piperacillin (4 g) plus ciprofloxacin (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: piperacillin (4 g) plus tazobactam (0.5 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: piperacillin (4 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: ciprofloxacin (400 mg)
Number of subjects: 12
Study: 7815670

Group type: EXPERIMENTAL
Intervention: Aminovenös‐N‐päd 10% (contains acetylated tyrosine and acetylated cysteine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaminolact 6.5% (does not contain acetylated amino acids)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Primène 10% (does not contain acetylated amino acids)
Number of subjects: 20
Study: 2529686

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (BE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocoagulation (EK)
Number of subjects: 0
Study: 31867673

Group type: EXPERIMENTAL
Intervention: Home-based delivery of a range of contraceptives
Number of subjects: 140
Study: 28643315

Group type: EXPERIMENTAL
Intervention: Nano carbon development combined with artery approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 70
Study: 25812179

Group type: EXPERIMENTAL
Intervention: Increased oral lingual pressure during swallowing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Typical swallows
Number of subjects: 20
Study: 23760668

Group type: EXPERIMENTAL
Intervention: Food-specific biofeedback
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Non-specific relaxation biofeedback
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 31
Study: 21907600

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg · day(‐1))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (650 mg · day(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (cellulose capsule)
Number of subjects: 7
Study: 19184028

Group type: EXPERIMENTAL
Intervention: Raj yoga program (bi-weekly for 12 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no yoga)
Number of subjects: 47
Study: 16982288

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 25 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 150
Study: 15896619

Group type: EXPERIMENTAL
Intervention: Novare Enclose II manual proximal anastomotic device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Partial side clamp for proximal anastomoses
Number of subjects: 30
Study: 11246309

Group type: EXPERIMENTAL
Intervention: Collaborative weaning plan (CWP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (historical controls)
Number of subjects: 0
Study: 11327442

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine (200 mg zidovudine three times daily + 0.75 mg zalcitabine three times daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Zidovudine monotherapy (200 mg three times daily)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 256

Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 256
Study: 8434265

Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education message and antimalarial drug intervention 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard malaria chemoprophylaxis program)
Number of subjects: 0
Study: 3315267

Group type: EXPERIMENTAL
Intervention: Treatment A - 8 mg/kg at 0700 hr and 4 mg/kg at 1900 hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment B - 6 mg/kg at 0700 hr and 6 mg/kg at 1900 hr
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment C - 4 mg/kg at 0700 hr and 8 mg/kg at 1900 hr
Number of subjects: 12
Study: 30917809

Group type: EXPERIMENTAL
Intervention: Bleaching with 40% hydrogen peroxide for 2×45 min with a 1-week interval
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without bleaching treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thermocycling (5000 cycles at 5°C and 55°C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: No thermocycling
Number of subjects: 48
Study: 28272596

Group type: EXPERIMENTAL
Intervention: Pharmacists obtaining admission medication histories (AMHs)
Number of subjects: 2
Study: 26100064

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 24485339

Group type: EXPERIMENTAL
Intervention: 5% sucrose solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Aspartate solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (pure water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cortisol levels after all treatments (sucrose, aspartate, placebo)
Number of subjects: 15
Study: 21480694

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 105
Study: 18992346

Group type: EXPERIMENTAL
Intervention: CYP2C9*3 allele
Number of subjects: 18

Group type: COMPARATOR
Intervention: CYP2C9*1 and *2 alleles
Number of subjects: 18

Group type: COMPARATOR
Intervention: CYP2C9*2 allele
Number of subjects: 18
Study: 16487833

Group type: EXPERIMENTAL
Intervention: Eptifibatide in high-risk group
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo in high-risk group
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Eptifibatide in low-risk group
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo in low-risk group
Number of subjects: 2064
Study: 15486840

Group type: COMPARATOR
Intervention: Conventional report (Group A)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Conventional report + written alert with clinical advice (Group B)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Conventional report + written alert + oral clinical advice (Group C)
Number of subjects: 297
Study: 11106526

Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: COMPARATOR
Intervention: ADCON-T/N and Control group
Number of subjects: 30
Study: 9527321

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 50 mg/day
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Beta-carotene 20 mg/day
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol or beta-carotene supplementation
Number of subjects: 1828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1828
Study: 7931205

Group type: EXPERIMENTAL
Intervention: Enhanced continuity of care
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Desipramine blood levels above 123 ng/ml at week 2
Number of subjects: 94
Study: 3203062

Group type: EXPERIMENTAL
Intervention: BN52063 (120 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled PAF
Number of subjects: 8
Study: 31591062

Group type: EXPERIMENTAL
Intervention: Gastrointestinal Artificial Intelligence Diagnostic System (GRAIDS)
Number of subjects: 84424

Group type: EXPERIMENTAL
Intervention: GRAIDS
Number of subjects: 84424

Group type: COMPARATOR
Intervention: Expert endoscopist
Number of subjects: 84424

Group type: COMPARATOR
Intervention: Competent endoscopist
Number of subjects: 84424

Group type: COMPARATOR
Intervention: Trainee endoscopist
Number of subjects: 84424
Study: 28177741

Group type: EXPERIMENTAL
Intervention: 5:40 (24 × 5‐s efforts, 40‐s recovery)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15:120 (8 × 15‐s efforts, 120‐s recovery)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 30:240 (4 × 30‐s efforts, 240‐s recovery)
Number of subjects: 9
Study: 25495716

Group type: EXPERIMENTAL
Intervention: Neg‐PTP
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Deliberation (for Neg‐PTP jurors)
Number of subjects: 320

Group type: COMPARATOR
Intervention: No‐PTP
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Discussion of ambiguous trial evidence
Number of subjects: 320
Study: 23426738

Group type: EXPERIMENTAL
Intervention: Argus II system on
Number of subjects: 28

Group type: COMPARATOR
Intervention: Argus II system off
Number of subjects: 28
Study: 21837302

Group type: EXPERIMENTAL
Intervention: Bilayer collagen matrix (CM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Autogenous gingival graft (AGG)
Number of subjects: 5
Study: 19040036

Group type: EXPERIMENTAL
Intervention: Healive (inactivated hepatitis A vaccine)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 400
Study: 16930367

Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS of LTA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of LTA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10‐Hz rTMS of mesial parietal cortex
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of LTA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 6
Study: 12569292

Group type: EXPERIMENTAL
Intervention: Fotemustine plus whole brain irradiation (arm B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Fotemustine alone (arm A)
Number of subjects: 76
Study: 12866325

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous (TAA AQ) 200 micrograms once daily (n = 75)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate aqueous (BDP) 336 micrograms twice daily (n = 77)
Number of subjects: 152
Study: 10783825

Group type: EXPERIMENTAL
Intervention: Erythromycin (2 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8876516

Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Number of subjects: 0
Study: 1633125

Group type: EXPERIMENTAL
Intervention: Information sheet sent to clients regarding initial assessment sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No information sheet sent to clients (Control group)
Number of subjects: 0
Study: 6743479

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once‐daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3534594

Group type: COMPARATOR
Intervention: 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 796

Group type: COMPARATOR
Intervention: BCG and postoperative irradiation
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Additional chemotherapy with alternate drugs after completion of FAC
Number of subjects: 796
Study: 31049783

Group type: EXPERIMENTAL
Intervention: Heated Tobacco Product (THP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Combustible Cigarette Smoking
Number of subjects: 280

Group type: COMPARATOR
Intervention: Smoking Cessation
Number of subjects: 280

Group type: COMPARATOR
Intervention: Never Smokers
Number of subjects: 280
Study: 28985716

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 110
Study: 26637514

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² as a two‐ to five‐minute i.v. infusion on days 1 and 8 of a 21‐day cycle
Number of subjects: 908
Study: 24189290

Group type: EXPERIMENTAL
Intervention: CapOpus (motivational interviewing and cognitive behavior therapy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 103
Study: 21226785

Group type: EXPERIMENTAL
Intervention: Imagery plus text
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Imagery only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Text only
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 19592546

Group type: EXPERIMENTAL
Intervention: Pin1 mRNA expression in patients with non-small-cell lung cancer
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pin1 mRNA expression in the distal part of the pulmonary vein
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Postoperative Pin1 mRNA expression
Number of subjects: 26

Group type: COMPARATOR
Intervention: Comparison of Pin1 expression based on pulmonary vessel ligation
Number of subjects: 26